Phase II study of neoadjuvant cemiplimab prior to surgery in patients with stage III/IV (M0) cutaneous squamous cell carcinoma of the head and neck (CSCC-HN)

MLA

R. Ferrarotto, et al. “Phase II Study of Neoadjuvant Cemiplimab Prior to Surgery in Patients with Stage III/IV (M0) Cutaneous Squamous Cell Carcinoma of the Head and Neck (CSCC-HN).” Annals of Oncology, vol. 30, Oct. 2019, p. v910. EBSCOhost, https://doi.org/10.1093/annonc/mdz394.071.

APA

R. Ferrarotto, Jason M. Johnson, Randal S. Weber, Diana Bell, M. Wong, Neil D. Gross, J.N. Myers, Bonnie S. Glisson, Bita Esmaeli, Ying Yuan, Priyadharsini Nagarajan, Michael R. Migden, David I. Rosenthal, Adel K. El-Naggar, & Jennifer A. Wargo. (2019). Phase II study of neoadjuvant cemiplimab prior to surgery in patients with stage III/IV (M0) cutaneous squamous cell carcinoma of the head and neck (CSCC-HN). Annals of Oncology, 30, v910. https://doi.org/10.1093/annonc/mdz394.071

Chicago

R. Ferrarotto, Jason M. Johnson, Randal S. Weber, Diana Bell, M. Wong, Neil D. Gross, J.N. Myers, et al. 2019. “Phase II Study of Neoadjuvant Cemiplimab Prior to Surgery in Patients with Stage III/IV (M0) Cutaneous Squamous Cell Carcinoma of the Head and Neck (CSCC-HN).” Annals of Oncology 30 (October): v910. doi:10.1093/annonc/mdz394.071.